Web12 apr. 2024 · Ionis Pharmaceuticals Stock Performance. IONS opened at $37.23 on Tuesday. Ionis Pharmaceuticals has a 12-month low of $31.46 and a 12-month high of $48.82. The stock has a market cap of $5.32 ... Web23 mrt. 2024 · About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of …
Archit Rastogi, PhD - Assistant Director, Preclinical
Web31 dec. 2024 · THIS LICENSE AGREEMENT IS ENTERED INTO BY THE FOLLOWING PARTIES: 1.Ionis Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, located at 2855 Gazelle Court, Carlsbad, CA 92010 U.S.A., hereinafter referred to as “Ionis”; AND. 2.ProQR Therapeutics IV B.V., a company organized under the laws of … Web11 apr. 2024 · La ricerca di Morgan Stanley conferma la raccomandazione e mantiene il giudizio Neutral. Il prezzo obiettivo è stato alzato ed è ora fissato a 42 USD rispetto ai precedenti 40 USD . 12 aprile 2024 circuit breaker it
Assessing mNIS+7Ionis and international …
Web28 feb. 2024 · Ionis reports fourth quarter and full year 2024 financial results. Feb 21, 2024. Ionis announces new donidalorsen data and presentations at the 2024 American Academy of Allergy, Asthma & … Web17 mrt. 2024 · Ionis provides full year 2024 financial guidance. CARLSBAD, Calif., Feb. 22, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), a genetic medicines company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial results are summarized below: WebIonis is focused on delivering RNA-targeted therapeutics with transformational potential. Our antisense oligonucleotide drug discovery platform has transformed the lives of patients with devastating diseases, including SMA, hATTR, and FCS. We have the potential to treat many additional diseases where other therapeutic approaches have proven ... diamondclean smart trial - black